MedTrace Logo

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

NCT06365840 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-17

No results posted yet for this study

Summary

The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.

Conditions

  • TMB-H
  • Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

Interventions

DRUG

IMC-001

All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.

Sponsors & Collaborators

  • ImmuneOncia Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • JEEYUN LEE · Samsung Medical Center, Republic of Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2027-06-30
Completion
2029-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365840 on ClinicalTrials.gov